Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy Buys 88,850 Shares

Pyxis Oncology, Inc. (NASDAQ:PYXS) CFO Pamela Ann Connealy purchased 88,850 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The shares were bought at an average cost of $1.96 per share, with a total value of $174,146.00. Following the transaction, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at $2,350,320.28. The trade was a 8.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Pyxis Oncology Price Performance

PYXS traded up $0.06 during trading on Wednesday, hitting $1.83. The company had a trading volume of 1,809,338 shares, compared to its average volume of 753,874. The company has a market cap of $108.83 million, a PE ratio of -1.78 and a beta of 1.27. The business has a 50-day moving average of $3.54 and a 200-day moving average of $3.56. Pyxis Oncology, Inc. has a 1-year low of $1.48 and a 1-year high of $6.85.

Institutional Trading of Pyxis Oncology

Several institutional investors have recently added to or reduced their stakes in PYXS. Fullcircle Wealth LLC acquired a new stake in Pyxis Oncology in the second quarter valued at $40,000. Intech Investment Management LLC acquired a new stake in Pyxis Oncology in the third quarter valued at $55,000. SG Americas Securities LLC acquired a new stake in Pyxis Oncology in the third quarter valued at $58,000. The Manufacturers Life Insurance Company acquired a new stake in Pyxis Oncology in the second quarter valued at $65,000. Finally, MetLife Investment Management LLC raised its holdings in shares of Pyxis Oncology by 41.1% during the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after purchasing an additional 5,484 shares during the period. 39.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Thursday, November 21st. Royal Bank of Canada upped their price target on shares of Pyxis Oncology from $7.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Stephens initiated coverage on shares of Pyxis Oncology in a research note on Friday, November 8th. They set an “overweight” rating and a $13.00 price objective for the company. Finally, William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.